Systemic scleroderma (SSC or systemic sclerosis) is an autoimmune disorder that results into scar tissues (fibrosis) on the skin and internal organs. The prevalence of systemic scleroderma is about 30-500 cases in 1 million with more common in women than men.
Know more about the disease, its causes, symptoms and diagnosis through the newsletter. DelveInsight brings to focus an autoimmune skin disorder that can be due to either or a combination of genetic and environmental factors.
The Systemic Scleroderma newsletter compiles the epidemiological scenario, treatment modalities, unmet needs prevalent and the emerging therapies in the SSD Market. It also focuses on recent ongoings on the R&D front, news coverings, major pharma players involved and collaborations and funding taking place in the domain.
Get the newsletter directly mailed to your email box by filling up a simple form towards your right. Join our Newsletter series and get rich insights delivered every week to you.
#DelveInsight, through its newsletter series, aims for increased awareness about the indication, its underlying causes, etiology, symptoms, and risk factors among its readers.
Know More About What's Covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- Pipeline drugs
- Clinical trials
- Top conferences
- Support from International organizations
- News Flash
- R&D in the field
- Key Companies
- Collaborations and deals in the domain
- Market insights
- Unmet needs
Have a copy of newsletter- https://www.delveinsight.com/whitepaper-newsletter/systemic-scleroderma-newsletter
#raredisease #rare #disease #medicalsciences #newsletter #promotion #covid19 #healthcare #business #systemicscleroderma #readerscommunity #readinglist #newsletterdesign
Comments
Post a Comment